Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, everyone. Damian here with a look at a resurgence in psychiatric drug development, a big day for biotech stocks, and some innovation in the world of quarterly earnings.
Biotech hit a two-year high — on its own merits
Things haven’t been this good for biotech since January 2022. The closely watched XBI biotech index crossed $100 yesterday, a roughly 6% one-day increase that completes a roughly two-year round trip for the sector.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect